337 related articles for article (PubMed ID: 37153556)
1. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.
Barkhordar M; Chahardouli B; Biglari A; Ahmadvand M; Bahri T; Alaeddini F; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Biglari M; Shemshadi MR; Ghavamzadeh A; Vaezi M
Front Immunol; 2023; 14():1169666. PubMed ID: 37153556
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Safety and Immunogenicity of a Recombinant Receptor-Binding Domain (RBD)-Tetanus Toxoid (TT) Conjugated SARS-CoV-2 Vaccine (PastoCovac) in Recipients of Autologous Hematopoietic Stem Cell Transplantation Compared to the Healthy Controls; A Prospective, Open-Label Clinical Trial.
Barkhordar M; Ahmadvand M; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Janbabai G; Sorouri R; Asadi Milani M; Vaezi M
Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36679963
[TBL] [Abstract][Full Text] [Related]
3. Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial.
Sharifi Aliabadi L; Karami M; Barkhordar M; Hashemi Nazari SS; Kavousi A; Ahmadvand M; Vaezi M
Front Immunol; 2023; 14():1237916. PubMed ID: 37593732
[TBL] [Abstract][Full Text] [Related]
4. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.
Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM
Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
Mittal A; Solera JT; Ferreira VH; Kothari S; Kimura M; Pasic I; Mattsson JI; Humar A; Kulasingam V; Ierullo M; Kumar D; Hosseini-Moghaddam SM
Transplant Cell Ther; 2023 Nov; 29(11):706.e1-706.e7. PubMed ID: 37582470
[TBL] [Abstract][Full Text] [Related]
6. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy.
Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š
Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792
[TBL] [Abstract][Full Text] [Related]
7. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.
Jullien M; Le Bourgeois A; Coste-Burel M; Peterlin P; Garnier A; Rimbert M; Imbert BM; Le Gouill S; Moreau P; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Vantyghem S; Béné MC; Guillaume T; Chevallier P
Transplant Cell Ther; 2022 May; 28(5):279.e1-279.e4. PubMed ID: 35218998
[TBL] [Abstract][Full Text] [Related]
8. Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity.
Einarsdottir S; Martner A; Waldenström J; Nicklasson M; Ringlander J; Arabpour M; Törnell A; Wiktorin HG; Nilsson S; Bittar R; Nilsson M; Lisak M; Veje M; Friman V; Al-Dury S; Bergström T; Ljungman P; Brune M; Hellstrand K; Lagging M
Blood Adv; 2022 May; 6(9):2723-2730. PubMed ID: 35286374
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation.
Hütter-Krönke ML; Neagoie A; Blau IW; Wais V; Vuong L; Gantner A; Ahn J; Penack O; Schnell J; Nogai KA; Eberspächer B; Saadati M; Benner A; Bullinger L; Döhner H; Bunjes D; Sala E
Front Immunol; 2023; 14():1174289. PubMed ID: 37207199
[TBL] [Abstract][Full Text] [Related]
10. Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients.
Canti L; Humblet-Baron S; Desombere I; Neumann J; Pannus P; Heyndrickx L; Henry A; Servais S; Willems E; Ehx G; Goriely S; Seidel L; Michiels J; Willems B; Liston A; Ariën KK; Beguin Y; Goossens ME; Marchant A; Baron F
J Hematol Oncol; 2021 Oct; 14(1):174. PubMed ID: 34689821
[TBL] [Abstract][Full Text] [Related]
11. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group.
Piñana JL; López-Corral L; Martino R; Montoro J; Vazquez L; Pérez A; Martin-Martin G; Facal-Malvar A; Ferrer E; Pascual MJ; Sanz-Linares G; Gago B; Sanchez-Salinas A; Villalon L; Conesa-Garcia V; Olave MT; López-Jimenez J; Marcos-Corrales S; García-Blázquez M; Garcia-Gutiérrez V; Hernández-Rivas JÁ; Saus A; Espigado I; Alonso C; Hernani R; Solano C; Ferrer-Lores B; Guerreiro M; Ruiz-García M; Muñoz-Bellido JL; Navarro D; Cedillo A; Sureda A;
Am J Hematol; 2022 Jan; 97(1):30-42. PubMed ID: 34695229
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
[TBL] [Abstract][Full Text] [Related]
14. Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.
Sharifi Aliabadi L; Azari M; Taherian MR; Barkhordar M; Abbas SAM; Azari M; Ahmadvand M; Salehi Z; Rouzbahani S; Vaezi M
Virol J; 2024 May; 21(1):103. PubMed ID: 38702752
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
16. Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.
Sherman AC; Cheng CA; Swank Z; Zhou G; Li X; Issa NC; Walt DR; Baden LR; Soiffer RJ
Transplant Cell Ther; 2023 May; 29(5):337.e1-337.e5. PubMed ID: 36736784
[TBL] [Abstract][Full Text] [Related]
17. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients.
Clémenceau B; Le Bourgeois A; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Jullien M; Ollier J; Grain A; Béné MC; Chevallier P
Cells; 2022 Sep; 11(19):. PubMed ID: 36230971
[TBL] [Abstract][Full Text] [Related]
18. Antibody, cell-mediated response and infection susceptibility in allogeneic hematopoietic stem cell recipients after COVID-19 mRNA vaccination.
Pizzano U; Facchin G; Marcon C; Fabris M; Battista ML; Cerno M; Geromin A; Pucillo M; Petruzzellis G; Vianello G; Battaglia G; Peressutti R; Grillone L; Tascini C; Curcio F; Fanin R; Patriarca F
Transpl Infect Dis; 2023 Apr; 25(2):e14003. PubMed ID: 36748718
[TBL] [Abstract][Full Text] [Related]
19. Robust spike-specific CD4
Federico L; Tvedt THA; Gainullin M; Osen JR; Chaban V; Lund KP; Tietze L; Tran TT; Lund-Johansen F; Kared H; Lind A; Vaage JT; Stratford R; Tennøe S; Malone B; Clancy T; Myhre AEL; Gedde-Dahl T; Munthe LA
Front Immunol; 2023; 14():1210899. PubMed ID: 37503339
[TBL] [Abstract][Full Text] [Related]
20. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
